AI Photoreceptor Mapping for GA Monitoring
- WAIKOLOA, Hawaii - Geographic atrophy is a growing worldwide health issue, with approximately 8 million patients impacted, according to a speaker.
- At Retina 2026, Healio | OSN associate medical editor Rishi P.
- Retina specialists should continue utilizing currently FDA-approved treatments for geographic atrophy (GA) as promising therapies like vonaprument and elamipretide are not expected to be widely available until 2028...
Key takeaways:
- Multimodal imaging and AI are both beneficial for managing patients with geographic atrophy.
- Cell therapies and visual cycle modulation are just two of many treatment avenues being studied.
WAIKOLOA, Hawaii – Geographic atrophy is a growing worldwide health issue, with approximately 8 million patients impacted, according to a speaker.
At Retina 2026, Healio | OSN associate medical editor Rishi P. Singh, MD, FASRS, delivered an expansive update on the GA treatment landscape.
new Treatments for Geographic Atrophy May Not Be Available Until 2028
Retina specialists should continue utilizing currently FDA-approved treatments for geographic atrophy (GA) as promising therapies like vonaprument and elamipretide are not expected to be widely available until 2028 or later, according to Sunil Singh, MD.
Researchers are currently investigating visual cycle modulation, cell therapy, and neuroprotection as potential mechanisms for future GA treatments. Therapies in development specifically for GA and wet age-related macular degeneration include vonaprument (Annexon Biosciences) and elamipretide (Stealth BioTherapeutics).
“The call to arms right now is that new drugs won’t be out until 2028 or beyond,” Singh said.”We have drugs right now in our practice. I would not recommend waiting 2 years before instituting these therapies in your own practice.”
Source: Healio/Ocular Surgery News